• NuCana published a corporate presentation outlining its ProTide platform and lead oncology programs NUC-7738 and NUC-3373.
• Presentation highlighted NuTide:701 data for NUC-7738, including a 41% disease control rate in efficacy-evaluable patients.
• Combination cohort showed a 55% tumor reduction in one patient; another achieved a 32% tumor reduction; one had ongoing complete metabolic response.
• Cash and cash equivalents were about $25.9 million as of June 30, 2026; cash runway projected into 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief on September 02, 2026, and is solely responsible for the information contained therein.